Crystalys Therapeutics Secures $130 Million in Latest Series B Funding Round

Crystalys Therapeutics secured $130 million in its latest Series B, adding another data point to the Healthcare & Life Sciences funding market.

Crystalys Therapeutics Raises $130 million in Funding

Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

Crystalys Therapeutics operates in Healthcare & Life Sciences. Crystalys Therapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout.

Looking Ahead

Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout

Source reference: original announcement/article.